The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

We recently compiled a list of the 7 Cheap Quarterly Dividend Stocks to Invest in. In this article, we are going to take a ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen (NASDAQ:AMGN – Free Report) had its price target decreased by Citigroup from $310.00 to $295.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a ...

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new opportunities to expand access to their medicines through PAPs.